Heron Therapeutics | HRTX - Operating Expenses


Heron Therapeutics reported $40.55M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
ALKERMES USD 1.81B 57.02M Jun/2026
Alnylam Pharmaceuticals USD 1.06B 160.97M Jun/2026
Amarin USD 51.48M 113K Dec/2025
ANI Pharmaceuticals USD 597.21M 34.91M Jun/2026
Anika Therapeutics USD 137.28M 3.38M Jun/2026
Arrowhead Research USD 245.35M 30.35M Jun/2026
Eisai JPY 209.6B 6.14B Jun/2026
Emergent BioSolutions USD 555.9M 242.7M Jun/2023
GlaxoSmithKline GBP 5.8B 468M Jun/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Insmed USD 526.79M 20.55M Jun/2026
Ligand Pharmaceuticals USD 55.1M 20.75M Jun/2026
Merck USD 15.77B 2.4B Jun/2026
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Neurocrine Biosciences USD 739.1M 139.2M Jun/2026
Omeros USD 59.16M 20.13M Jun/2024
Pacira USD 180.54M 7.79M Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Ultragenyx Pharmaceutical USD 289M 16M Jun/2026
Veracyte USD 126.36M 6.37M Jun/2026
Vertex Pharmaceuticals USD 2.07B 217.1M Jun/2026